These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 11845103

  • 1. [Cost of cardiovascular risk factor prevention in middle-aged French men. The PRIME study].
    Marques-Vidal P, Arveiler D, Amouyel P, Ducimetière P, Ferrières J.
    Rev Epidemiol Sante Publique; 2001 Dec; 49(6):541-9. PubMed ID: 11845103
    [Abstract] [Full Text] [Related]

  • 2. [Medical cost of cardiovascular risk factors prevention in France].
    Marques-Vidal P, Bongard V, Arveiler D, Amouyel P, Ducimetière P, Ferrières J.
    Arch Mal Coeur Vaiss; 2002 Apr; 95(4):275-81. PubMed ID: 12055766
    [Abstract] [Full Text] [Related]

  • 3. How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city.
    Tang JL, Wang WZ, An JG, Hu YH, Cheng SH, Griffiths S.
    Int J Epidemiol; 2010 Feb; 39(1):244-54. PubMed ID: 19491141
    [Abstract] [Full Text] [Related]

  • 4. Influence of parental histories of cardiovascular risk factors on risk factor clusters in the offspring.
    Lascaux-Lefebvre V, Ruidavets JB, Arveiler D, Amouyel P, Haas B, Cottel D, Bingham A, Ducimetière P, Ferrières J.
    Diabetes Metab; 2001 Sep; 27(4 Pt 1):503-9. PubMed ID: 11547225
    [Abstract] [Full Text] [Related]

  • 5. Sex differences in risk factor control of treated hypertensives: a national primary healthcare-based study in Sweden.
    Journath G, Hellénius ML, Petersson U, Theobald H, Nilsson PM, Hyper-Q Study Group Sweden.
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):258-62. PubMed ID: 18525379
    [Abstract] [Full Text] [Related]

  • 6. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
    Qiu YG, Yao XY, Tao QM, Zheng P, Chen JZ, Zhu JH, Zhang FR, Zheng LR, Zhao LL.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
    [Abstract] [Full Text] [Related]

  • 7. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
    Xhignesse M, Laplante P, Niyonsenga T, Courteau J, Grant AM.
    Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
    [Abstract] [Full Text] [Related]

  • 8. Education, socioeconomic and lifestyle factors, and risk of coronary heart disease: the PRIME Study.
    Yarnell J, Yu S, McCrum E, Arveiler D, Hass B, Dallongeville J, Montaye M, Amouyel P, Ferrières J, Ruidavets JB, Evans A, Bingham A, Ducimetière P, PRIME study group.
    Int J Epidemiol; 2005 Apr; 34(2):268-75. PubMed ID: 15319403
    [Abstract] [Full Text] [Related]

  • 9. [Great discrepancies between European, Dutch and Belgian criteria for the use of statins in the prevention of primary cardiovascular disease in family practice].
    Van Diest E, Stoffelen E, Wydooghe L, Van Duppen D, Seuntjens L, Van der Stuyft P.
    Ned Tijdschr Geneeskd; 2001 Feb 24; 145(8):361-6. PubMed ID: 11257816
    [Abstract] [Full Text] [Related]

  • 10. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J, López-Gómez JM, Aljama P.
    Nefrologia; 2005 Feb 24; 25(3):297-306. PubMed ID: 16053011
    [Abstract] [Full Text] [Related]

  • 11. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T.
    Eur J Cardiovasc Prev Rehabil; 2006 Aug 24; 13(4):523-8. PubMed ID: 16874140
    [Abstract] [Full Text] [Related]

  • 12. Cost of renal transplant maintenance immunosuppression: effect of control of vascular risk factors.
    Gentil MA, López M, González-Roncero F, Cantarell C, Marco J.
    Transplant Proc; 2005 Apr 24; 37(3):1464-5. PubMed ID: 15866640
    [Abstract] [Full Text] [Related]

  • 13. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
    Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L.
    Int J Technol Assess Health Care; 2007 Apr 24; 23(1):71-9. PubMed ID: 17234019
    [Abstract] [Full Text] [Related]

  • 14. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z, Liew D, Chew D, Conner G, Shiel L, Nelson M, Soman A, Steg G, Bhatt DL, Reid C, REACH registry investigators.
    Cardiovasc Ther; 2009 Apr 24; 27(3):164-72. PubMed ID: 19689615
    [Abstract] [Full Text] [Related]

  • 15. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ, Ishola DA, Akintomide AO, Ajayi AA.
    J Hum Hypertens; 2003 Apr 24; 17(4):277-85. PubMed ID: 12714973
    [Abstract] [Full Text] [Related]

  • 16. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 24; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 17. [Estimation of the number of patients treated for hypertension, diabetes or hyperlipidemia in France: FLAHS study 2002].
    Girerd X, Mourad JJ, Vaïsse B, Poncelet P, Mallion JM, Herpin D.
    Arch Mal Coeur Vaiss; 2003 Oct 24; 96(7-8):750-3. PubMed ID: 12945216
    [Abstract] [Full Text] [Related]

  • 18. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA, Koro CE, Chan W, Bowlin SJ, Sprecher DL.
    Clin Ther; 2006 Feb 24; 28(2):243-50. PubMed ID: 16678645
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group.
    Clin Ther; 2006 Mar 24; 28(3):432-44. PubMed ID: 16750458
    [Abstract] [Full Text] [Related]

  • 20. The cost of treating high blood pressure in general practice in France.
    Tibi-Levy Y, de Pouvourville G, Westerloppe J, Bamberger M.
    Eur J Health Econ; 2008 Aug 24; 9(3):229-36. PubMed ID: 17566802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.